The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Sonrotoclax monotherapy in R/R Waldenström’s macroglobulinemia: initiation of BGB-11417-203
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the encouraging data for sonrotoclax monotherapy in relapsed/refractory (R/R) Waldenström’s macroglobulinemia. Dr Cheah highlights the encouraging responses observed, leading to the initiation of the Phase II BGB-11417-203 study (NCT05952037). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The sonrotoclax data in Waldenstrom is also encouraging. I mean this is a drug which is highly potent in a range of B-cell malignancies. We know that venetoclax has some activity in Waldenstrom macroglobulinemia but we’ve updated the results of sonrotoclax in about 24 patients with relapsed and refractory WM, and we’re continuing to see increasing depth and durability of responses there...
The sonrotoclax data in Waldenstrom is also encouraging. I mean this is a drug which is highly potent in a range of B-cell malignancies. We know that venetoclax has some activity in Waldenstrom macroglobulinemia but we’ve updated the results of sonrotoclax in about 24 patients with relapsed and refractory WM, and we’re continuing to see increasing depth and durability of responses there. The activity has been sufficient that this is now moving forward into a phase two study in Waldenstrom macroglobulinemia called the 203 study, for which enrollment continues.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
